Machine-assisted translation — the German original version is authoritative.
Metabolism & Weight
Retatrutid
LY3437943
Retatrutide is an experimental triple receptor agonist (GIP, GLP-1 and glucagon) from Eli Lilly. It is in clinical trials and is not approved as a medicine anywhere. It is legally available only within controlled studies — not as a consumer product.
Regulatory status
In clinical trials only · not approved
Investigational substance without approval — outside clinical trials there is no legitimate human use.
Drug class
Triple GIP/GLP-1/glucagon receptor agonist (experimental)
Half-life (informative)
approx. 6 days (weekly administration in studies)
Studied in the literature
In clinical studies subcutaneous, under strict study control.
Mechanism of action
Retatrutide activates three receptors: GIP and GLP-1 (like tirzepatide) plus the glucagon receptor. The additional glucagon component is intended to increase energy expenditure. The mechanism is promising, but long-term safety and the ultimate benefit have not yet been conclusively established.
All data come from ongoing/completed studies; a definitive safety profile is not yet available.
Research history
Phase 2 results for obesity were published in 2023 (including in the NEJM) and showed pronounced weight effects. Initial positive Phase 3 data from the TRIUMPH program (including TRIUMPH-1) were reported in 2026, with pronounced weight effects over long study periods. The status remains unchanged: until testing is complete and a regulatory approval is granted, retatrutide is considered an investigational substance.
Regulatory status by region
Not an approved medicine. Available only within authorized clinical trials.
Currently in FDA-regulated studies; no marketing authorization.
Research areas
- Obesity (TRIUMPH program)
- Type 2 diabetes
- Investigated in MASH and knee osteoarthritis, among others
Documented effects (from the literature)
- In studies, dose-dependent gastrointestinal effects (nausea, diarrhea, vomiting).
- Pronounced weight loss in Phase 2 data.
- Observed effects on heart rate in studies.
Safety concerns & caution
- Long-term safety not established — the substance is still under investigation.
- Complete side-effect and contraindication profile not yet finalized.
- The glucagon component requires particular monitoring (e.g. glucose, heart rate).
- At higher dose levels, an unusual skin sensitivity (dysesthesia, tingling) was reported more frequently — a signal distinct to retatrutide.
Risks of gray-market purchase
- Retatrutide sold online as a "research peptide" completely bypasses clinical testing.
- There is no established safe use outside of studies — quality, identity and purity are unassured.
- Obtaining/possessing unapproved active substances can be legally problematic.
Frequently asked questions
Can I obtain retatrutide legally?
Legitimately only by participating in a registered clinical trial. It is not an approved product and not a legal consumer good.
Why is it sold online if it is not approved?
Such offers use the "Research Use Only" cover to bypass pharmaceutical regulation. That makes the substance neither tested nor safe.
Is it "better" than tirzepatide?
The Phase 2 data are impressive, but a comparison is premature: without completed Phase 3 and approval, robust long-term safety and efficacy data are lacking.
Retatrutide now has positive Phase 3 data — does that make it safe?
No. Since 2026, initial positive Phase 3 data (the TRIUMPH program) with pronounced weight effects are available, but retatrutide is still not approved as a medicine anywhere and remains an investigational substance. At higher dose levels, an unusual skin sensitivity also occurred more frequently. A positive study result is not a seal of safety — outside of a study, obtaining it completely bypasses the ongoing regulatory review.
Sources
Primary and reference sources for your own reading.
Related substances
Unfamiliar terms? Look them up in the glossary or read the fundamentals.
This profile is for information and education only. It is not medical advice and deliberately contains no dosing or usage details. Decisions about use belong in a doctor’s hands.